Sunil R Hingorani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4248651/publications.pdf

Version: 2024-02-01

79 papers	17,947 citations	94269 37 h-index	71532 76 g-index
80 all docs	80 docs citations	80 times ranked	20411 citing authors

#	Article	IF	Citations
1	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	6.0	2,730
2	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	7.7	2,150
3	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	7.7	2,137
4	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
5	Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 21, 418-429.	7.7	1,664
6	ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8, 311-321.	7.7	866
7	Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion. Cancer Research, 2007, 67, 9518-9527.	0.4	838
8	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	7.7	710
9	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, 2018, 36, 359-366.	0.8	350
10	KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas. Cancer Cell, 2007, 11, 229-243.	7.7	327
11	Photostable Ratiometric Pdot Probe for in Vitro and in Vivo Imaging of Hypochlorous Acid. Journal of the American Chemical Society, 2017, 139, 6911-6918.	6.6	311
12	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut, 2014, 63, 1769-1781.	6.1	272
13	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2848-2854.	3.2	272
14	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 3185-3194.	0.8	233
15	Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal of Clinical Oncology, 2019, 37, 1062-1069.	0.8	212
16	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell, 2015, 161, 1345-1360.	13.5	175
17	Hypoxia Triggers Hedgehog-Mediated Tumorâ€“Stromal Interactions in Pancreatic Cancer. Cancer Research, 2013, 73, 3235-3247.	0.4	170
18	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research, 2017, 5, 978-991.	1.6	170

#	Article	IF	Citations
19	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2015, 28, 638-652.	7.7	168
20	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research, 2008, 14, 4836-4842.	3.2	136
21	Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. Biophysical Journal, 2016, 110, 2106-2119.	0.2	131
22	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist, 2015, 20, 143-150.	1.9	123
23	The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression. Cancer Research, 2007, 67, 6075-6082.	0.4	108
24	Stromal reengineering to treat pancreas cancer. Carcinogenesis, 2014, 35, 1451-1460.	1.3	108
25	Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2016, 150, 1545-1557.e2.	0.6	101
26	Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Current Oncology Reports, 2017, 19, 47.	1.8	100
27	Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancerâ€“Associated Fibroblasts. Cancer Discovery, 2022, 12, 484-501.	7.7	97
28	Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. Gastroenterology, 2019, 156, 2085-2096.	0.6	93
29	Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable Pdots. Nature Communications, 2016, 7, 11468.	5.8	85
30	Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics and Development, 2003, 13, 6-13.	1.5	80
31	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Research, 2015, 75, 3738-3746.	0.4	76
32	Ductal Pancreatic Cancer in Humans and Mice. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 65-72.	2.0	75
33	Reâ€adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews, 2014, 257, 145-164.	2.8	67
34	Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research, 2019, 7, 977-989.	1.6	45
35	Molecular Pathways: Myeloid Complicity in Cancer. Clinical Cancer Research, 2014, 20, 5157-5170.	3.2	44
36	Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer. Clinical Cancer Research, 2015, 21, 1764-1771.	3.2	42

#	Article	IF	Citations
37	Isoform-Specific Upregulation of Palladin in Human and Murine Pancreas Tumors. PLoS ONE, 2010, 5, e10347.	1.1	42
38	Mutant p53 Together with TGFÎ² Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1607-1620.	3.2	37
39	Vitamin E Î´-Tocotrienol Prolongs Survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) Transgenic Mouse Model of Pancreatic Cancer. Cancer Prevention Research, 2013, 6, 1074-1083.	0.7	35
40	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. International Journal of Hyperthermia, 2018, 34, 284-291.	1.1	35
41	N-Cadherin and Keratinocyte Growth Factor Receptor Mediate the Functional Interplay between Ki -RAS G12V and p53 V143A in Promoting Pancreatic Cell Migration, Invasion, and Tissue Architecture Disruption. Molecular and Cellular Biology, 2006, 26, 4185-4200.	1.1	34
42	Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E Â-tocotrienol. Carcinogenesis, 2013, 34, 858-863.	1.3	34
43	Measuring the Economic Burden of Disease and Injury in Korea, 2015. Journal of Korean Medical Science, 2019, 34, e80.	1.1	33
44	Evaluation of Renal Stone Comminution and Injury by Burst Wave Lithotripsy in a Pig Model. Journal of Endourology, 2019, 33, 787-792.	1.1	29
45	High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.. Journal of Clinical Oncology, 2015, 33, 4006-4006.	0.8	27
46	Targeting oncogene dependence and resistance. Cancer Cell, 2003, 3, 414-417.	7.7	26
47	Response to Chauhan et al.: Interstitial Pressure and Vascular Collapse in Pancreas Cancerâ€"Fluids and Solids, Measurement and Meaning. Cancer Cell, 2014, 26, 16-17.	7.7	25
48	Changes in Connexin43 Expression and Localization During Pancreatic Cancer Progression. Journal of Membrane Biology, 2012, 245, 255-262.	1.0	23
49	Spatiotemporal Proteomic Analyses during Pancreas Cancer Progression Identifies Serine/Threonine Stress Kinase 4 (STK4) as a Novel Candidate Biomarker for Early Stage Disease. Molecular and Cellular Proteomics, 2014, 13, 3484-3496.	2.5	21
50	Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma. Cancers, 2019, 11, 772.	1.7	18
51	Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imaging. Cancer Medicine, 2017, 6, 1082-1090.	1.3	17
52	Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, 439-439.	0.8	17
53	In Search of an Early Warning System for Pancreatic Cancer. Cancer Biology and Therapy, 2003, 2, 85-87.	1.5	15
54	Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 359-359.	0.8	15

#	Article	IF	Citations
55	Disconnect between EMT and metastasis in pancreas cancer. Oncotarget, 2015, 6, 30445-30446.	0.8	15
56	Simultaneous robotic low anterior resection and prostatectomy for adenocarcinoma of rectum and prostate: initial case report. SpringerPlus, 2016, 5, 1768.	1.2	14
57	Location, Location, Location: Precursors and Prognoses for Pancreatic Cancer. Gastroenterology, 2007, 133, 345-350.	0.6	13
58	Runx3 and Cell Fate Decisions in Pancreas Cancer. Advances in Experimental Medicine and Biology, 2017, 962, 333-352.	0.8	13
59	Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI. Cancer Imaging, 2018, 18, 41.	1.2	13
60	Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy. Cancer Cell, 2015, 28, 151-153.	7.7	12
61	Targets, Trials, and Travails in Pancreas Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 1042-1053.	2.3	10
62	Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins. Radiology, 2016, 279, 400-409.	3.6	10
63	Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends in Cancer, 2018, 4, 273-277.	3.8	9
64	RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. Molecular and Cellular Oncology, 2016, 3, e1076588.	0.3	8
65	Cholesterol Biosynthesis Influences Subtype Specificity and Plasticity in Pancreas Cancer. Cancer Cell, 2020, 38, 443-445.	7.7	8
66	Magnetic resonance imaging biomarkers for pulsed focused ultrasound treatment of pancreatic ductal adenocarcinoma. World Journal of Gastroenterology, 2020, 26, 904-917.	1.4	8
67	Pancreas Cancer Meets the Thunder God. Science Translational Medicine, 2012, 4, 156ps21.	5.8	7
68	Cellular and molecular conspirators in pancreas cancer. Carcinogenesis, 2014, 35, 1435-1435.	1.3	6
69	Cx43 phosphorylation sites regulate pancreatic cancer metastasis. Oncogene, 2021, 40, 1909-1920.	2.6	6
70	Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. , 2022, 10, e003525.		5
71	Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer Journal (Sudbury, Mass), 2017, 23, 326-332.	1.0	4
72	A BODIPYâ€Based Donor/Donorâ€“Acceptor System: Towards Highly Efficient Longâ€Wavelengthâ€Excitable Nearâ€IR Polymer Dots with Narrow and Strong Absorption Features. Angewandte Chemie, 2019, 131, 7082-7086.	1.6	4

#	Article	IF	Citations
73	Non-Invasive Monitoring of Increased Fibrotic Tissue and Hyaluronan Deposition in the Tumor Microenvironment in the Advanced Stages of Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 999.	1.7	4
74	An in vivo demonstration of efficacy and acute safety of burst wave lithotripsy using a porcine model. Proceedings of Meetings on Acoustics, 2018, 35, .	0.3	3
75	From Inception to Invasion: Modeling Pathways to Pancreatic Cancer. , 2008, , 159-179.		3
76	A New Preclinical Paradigm for Pancreas Cancer. , 2010, , 73-93.		2
77	New Pathways to Pancreatic Cancer. Cancer Biology and Therapy, 2004, 3, 170-172.	1.5	1
78	Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the Chrysalis of Genotype?. Cancer Cell, 2016, 29, 780-782.	7.7	1
79	Increased tumour burden alters skeletal muscle properties in the KPC mouse model of pancreatic cancer. JCSM Rapid Communications, 2020, 3, 44-55.	0.6	1